openPR Logo
Press release

Systemic Scleroderma Treatment Market to Reach $1.99 Billion by 2028 | Pfizer, Bayer AG, GlaxoSmithKline, Novartis AG

11-24-2021 10:20 AM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Systemic Scleroderma Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Systemic Scleroderma Treatment industry with an attention on the Global market. The report gives key insights available status of the Systemic Scleroderma Treatment producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2021-2028 worldwide Systemic Scleroderma Treatment Market covering extremely significant parameters.

Request Sample Report + Related Graphs & Charts @:
https://www.coherentmarketinsights.com/insight/request-sample/4641

Key Players in This Report Include Boehringer Ingelheim International GmbH, Pfizer Inc., Bayer AG, GlaxoSmithKline plc., Novartis AG, Gilead Sciences, Inc., United Therapeutics, Hoffmann La Roche Ltd., Eli Lilly and Co., and Teva Pharmaceutical Industries Ltd.

Brief Summary of Systemic Scleroderma Treatment:

Scleroderma is a rare autoimmune rheumatic and connective tissue disease that causes inflammation of the skin and other parts of the body.

In the early stages of the disease, Systemic Scleroderma may only affect the skin. Symptoms include skin thickening developing around the mouth, nose, fingers, and other bony areas.

Scleroderma can have varying degrees of impact on the function of the heart, lungs, and kidneys. If left untreated, these issues can become life-threatening.

Market players are focused on product launches and approvals from regulatory authorities, this could contribute to the growth of the global systemic scleroderma treatment market over the forecast period. For instance, on January 12, 2021, Timber Pharmaceuticals Inc., a U.S.-based biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, confirmed that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation to TMB-003, Timber's locally delivered formulation of sitaxsentan, for the treatment of systemic sclerosis.

Market players are focusing on product approvals from regulatory authorities, which is expected to strengthen their position in the global systemic scleroderma treatment market. For instance, on May 28, 2020, Theraly Fibrosis, a U.S.-based preclinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had given Orphan Drug Designation (ODD) to TLY012 for the treatment of systemic sclerosis. TLY012 is a proprietary version of the recombinant human TRAIL protein with increased potency, stability, and bloodstream half-life. ODD status is granted by the U.S. FDA to medicines which are intended for the treatment, diagnosis, or prevention of rare diseases or disorders affecting fewer than 200,000 people in the U.S.

The Global Systemic Scleroderma Treatment Market segments and Market Data Break Down are illuminated below:

By Drug Class:
Immunosuppressant
Phosphodiesterase 5 Inhibitors (PHA)
Endothelin Receptor Antagonists
Prostacyclin Analogues
Calcium Channel Blockers
Others

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

This research report represents a 360-degree overview of the competitive landscape of the Global Systemic Scleroderma Treatment Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Systemic Scleroderma Treatment Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Systemic Scleroderma Treatment Market:

The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
North America (United States, Mexico & Canada)
South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

Request for customization in Report @ https://www.coherentmarketinsights.com/insight/request-customization/4641

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Systemic Scleroderma Treatment Market.

The detailed elaboration of the Global Systemic Scleroderma Treatment Market has been provided by applying industry analysis techniques such as SWOT and Porter’s five-technique. Collectively, this research report offers a reliable evaluation of the global market to present the overall framework of businesses.

Attractions of the Systemic Scleroderma Treatment Market Report:

• The report provides granular level information about the market size, regional market share, historic market (2016-2020) and forecast (2021-2028)

• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies

• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market

• The report tracks recent innovations, key developments and start-up’s details that are actively working in the market

• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/4641

Systemic Scleroderma Treatment Market research provides answers to the following key questions:

• What is the expected growth rate of the Systemic Scleroderma Treatment Market?

• What will be the Systemic Scleroderma Treatment Market size for the forecast period, 2021–2028?

• What are the main driving forces responsible for changing the Systemic Scleroderma Treatment Market trajectory?

• Who are the big suppliers that dominate the Systemic Scleroderma Treatment Market across different regions? Which are their wins to stay ahead in the competition?

• What are the Systemic Scleroderma Treatment Market trends business owners can rely upon in the coming years?

• What are the threats and challenges expected to restrict the progress of the Systemic Scleroderma Treatment Market across different countries?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Middle East, Africa, Europe or LATAM, Southeast Asia.

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Systemic Scleroderma Treatment Market to Reach $1.99 Billion by 2028 | Pfizer, Bayer AG, GlaxoSmithKline, Novartis AG here

News-ID: 2472783 • Views: 236

More Releases from Coherent Market Insights (CMI)

Hyperbaric Oxygen Therapy (HBOT) Devices Market 2021-2028 | Fink Engineering Pty …
Growing prevalence of diabetic foot ulcers is expected to grow the need for hyperbaric oxygen therapy devices, which is expected to boost the global hyperbaric oxygen market growth during the forecast period. According to the National Center for Biotechnology Information, the prevalence of diabetic foot ulcers (DFU) among hospitalized patients in China ranged from 4% - 10% in 2015. Request Sample Report + Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/553 Key Players in This
3D Cell Culture Market is Expected to Exhibit a CAGR of 23.4% by forecast 2021-2 …
Growing cases infectious diseases and cancer is expected to boost the global 3D cell culture market growth over the forecast period. Moreover, increasing demand for 3D cell culture for treatment of numerous diseases is expected to accelerate the market growth in the near future. According to the World Health Organization (WHO), September 2018 data finding, cancer is the second leading cause of death globally, and is responsible for an estimated
Life Sciences BPO Market 2021-2028 | Booming Globally with Catalent, Boehringer …
In life sciences, research and development BPO services include biometric, competitive intelligence pipeline research, R&D portfolio management, and more. Furthermore, drug development services include clinical data management, regulatory services, and pharmacovigiliance. The global life sciences BPO market is projected to account for US$ 667.3 Bn in terms of value by the end of 2027. Request Sample Report + Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/24 Key Players in This Report Include Catalent, Boehringer Ingelheim
Urea Breath Test Market to Reach $157.2 Million, at 5.1% CAGR by 2028 | Mayoli S …
Urea Breath Test Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Urea Breath Test industry with an attention on the Global market. The report gives key insights available status of the Urea Breath Test producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside

All 5 Releases


More Releases for Scleroderma

Scleroderma Therapeutics Market Analysis - Forecast to 2026
As per the research conducted by GME, the Global Scleroderma Therapeutics Market will grow with a CAGR value of 6.1 percent. Moreover, the rising R&D activities along with the advancing technology and increasing government spending in the pharma industry has boosted the market and growth will be seen in the future. Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Scleroderma Therapeutics Market
Global Scleroderma Therapeutics Market Size & Growth Analysis Report, 2020-2026
The global scleroderma therapeutics market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, rising investment in the R&D of drugs for its treatment, the emergence of new novel therapies, and new product launches are some of the key factors contributing to the growth of the scleroderma therapeutics market across the globe. According to the American College of Rheumatology, scleroderma is a relatively rare
Scleroderma Therapy Solutions Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Scleroderma Therapy Solutions industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Scleroderma Therapy Solutions and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Global Scleroderma Therapy Solutions Market Overview: GLOBAL INFO RESEARCH has evaluated the global Scleroderma Therapy Solutions market in its latest research report. The research report,
Develop Business Strategies Of Systemic Sclerosis (Scleroderma) Market 2024
"The Latest Research Report OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) - Opportunity Analysis and Forecast to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Systemic Sclerosis (Scleroderma) Market Systemic sclerosis (SSc) is a complex autoimmune disease that affects the skin and multiple internal organs. Common manifestations of SSc that are included in this report are skin fibrosis, lung fibrosis, and digital vasculopathy (including
Systemic Sclerosis (Scleroderma) Pharmaceutical and Healthcare Pipeline Review H …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246543 Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues.
Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast 2017-2021
Scleroderma is an autoimmune disease affecting the skin and other organs of the body. There are two main types of the disease: the localized form (called localized scleroderma, limited scleroderma, or morphea) and the systemic form (called systemic scleroderma, diffuse scleroderma, generalized scleroderma, or systemic sclerosis). Laboratory testing can identify antitopoisomerase or anticentromere antibodies. X-rays and computerized tomography (CT) scans are used to look at bone abnormalities. Thermography can detect